data in Biological Technology

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug data, positive drug sales/earnings and partnering and M&A deals. As a result, the Burrill Biotech Select Index posted a solid monthly gain of 6.5 percent, mirroring the Dow and Nasdaq, which closed the mon...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer...

iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies

Establishes New Throughput Standard in Cardiac Core Lab Industry Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has processed a total of 45 millio...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

DALLAS, July 23 /PRNewswire-FirstCall/ -- AC C E S S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , announced today that its European partner, SpePharm , is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing...

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and result...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publi...

New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue

CAMBRIDGE, Mass., July 6 /PRNewswire/ -- OmniGuide, Inc., the developer of the first and only flexible CO2 laser fiber based on breakthrough photonic bandgap technology, today announced the results of a pre-clinical study comparing the Company's fiber scalpels to conventional incision methods in...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ) today announced results from the Phas...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide cov...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years o...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the ...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

PRINCETON, N.J., June 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in leukemia were presented at the 14th Co...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

SAN DIEGO , June 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced positive secondary findings from the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltre...

Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blina...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that the US Food and Drug Adminis...

PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer

KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School , and the Dana-Far...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AE...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 i...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by ...

Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer - - Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types - TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceutical...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT ) announced today that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco's multiple myeloma studies at...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

THE WOODLANDS, Texas, May 27 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving oral presentations on two of its c...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting BETHESDA, Md., May 20 /PRNewswire-FirstCall/ --...

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week

First-in-class Oral Therapeutic for IBD with Novel Mode of Action MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical tria...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma an...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan Drug Designation ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

BOTHELL, WA and VANCOUVER, May 14 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced the release of two abstracts to be presented during oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts are now availab...

Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference

CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., May 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt(TM) (iloperidone), at the 162nd American Psychiatric Association (APA) annual meeting in San Francisco, Ca...

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04...

GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform

DigEx Solution offers completely interactive gene-level database to explore, understand, manage, and share next-generation sequencing DigEx runs. WESTBOROUGH, Mass., May 5 /PRNewswire/ -- GenomeQuest, Inc., the leader in sequence data management, today announced that it has released a Digital...

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today announced that the independent Data Monitoring Committee (DMC), after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conf...